Business Description
Celadon Pharmaceuticals PLC
ISIN : GB00BDQYGP38
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.27 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 1.49 | |||||
Debt-to-EBITDA | -0.74 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | -1.51 | |||||
Beneish M-Score | -3.22 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -125.4 | |||||
3-Year EPS without NRI Growth Rate | -82.3 | |||||
3-Year FCF Growth Rate | -98.7 | |||||
3-Year Book Growth Rate | 190.4 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 26.21 | |||||
9-Day RSI | 30.67 | |||||
14-Day RSI | 34.74 | |||||
6-1 Month Momentum % | 0.5 | |||||
12-1 Month Momentum % | -35.56 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.62 | |||||
Quick Ratio | 2.51 | |||||
Cash Ratio | 1.32 | |||||
Days Sales Outstanding | 2508.77 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.4 | |||||
Shareholder Yield % | -0.13 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -8288 | |||||
Net Margin % | -9520 | |||||
FCF Margin % | -8417.33 | |||||
ROE % | -154.72 | |||||
ROA % | -67.08 | |||||
ROIC % | -81.56 | |||||
ROC (Joel Greenblatt) % | -108.08 | |||||
ROCE % | -73.19 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 830 | |||||
PB Ratio | 16.94 | |||||
Price-to-Tangible-Book | 20.75 | |||||
EV-to-EBIT | -8.38 | |||||
EV-to-EBITDA | -9.08 | |||||
EV-to-Revenue | 773.68 | |||||
EV-to-FCF | -9.19 | |||||
Earnings Yield (Greenblatt) % | -11.93 | |||||
FCF Yield % | -11.57 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Celadon Pharmaceuticals PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil £) | 0.075 | ||
EPS (TTM) (£) | -0.115 | ||
Beta | 0 | ||
Volatility % | 196.09 | ||
14-Day RSI | 34.74 | ||
14-Day ATR (£) | 0.083219 | ||
20-Day SMA (£) | 0.94475 | ||
12-1 Month Momentum % | -35.56 | ||
52-Week Range (£) | 0.73437 - 1.7 | ||
Shares Outstanding (Mil) | 65.74 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Celadon Pharmaceuticals PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Celadon Pharmaceuticals PLC Stock Events
Event | Date | Price(£) | ||
---|---|---|---|---|
No Event Data |
Celadon Pharmaceuticals PLC Frequently Asked Questions
What is Celadon Pharmaceuticals PLC(LSE:CEL)'s stock price today?
When is next earnings date of Celadon Pharmaceuticals PLC(LSE:CEL)?
Does Celadon Pharmaceuticals PLC(LSE:CEL) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |